CClinicalTrials.gg
RecruitingNCT05660031Updated Apr 25, 2025

Treatment of the Biceps With Concomitant Supraspinatus Tears

An interventional study of LHB Tenotomy and LHB Tenodesis in Supraspinatus Tear, sponsored by La Tour Hospital. Recruiting at 4 sites in 3 countries. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-25.

Sponsored by La Tour Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 6 months after the study started (first participant enrolled Jun 2021, registered Dec 2022).
  • Started Jun 2021; still recruiting 5 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Study summary

The long head of the biceps (LHB) tendon is thought to be a common source of shoulder pain and dysfunction in patients with rotator cuff pathology. Tenotomy and tenodesis have been shown to produce favourable and comparable results in treating LHB lesions, but a controversy still exists regarding the treatment of choice. Some suggest that tenotomy should be reserved for older, low-demand patients, while tenodesis should be performed in younger patients and those who engage in heavy labor. Proponents of tenotomy suggest that this is a technically easy procedure that leads to easy rehabilitation and fast return to activity with a low complication and reoperation rate. However, those who support LHB tenodesis list good preservation of elbow flexion and supination strength, improvement of functional scores, elimination of pain, and avoidance of cosmetic deformity as benefits of the procedure. Alternatively, the LHB can be maintained in the joint without tenodesis or tenotomy. In fact, it has not been clearly shown that LHB tenodesis or tenotomy leads to improved outcomes compared to leaving the biceps tendon intact.

Read the detailed description

The long head of the biceps (LHB) tendon is thought to be a common source of shoulder pain and dysfunction in patients with rotator cuff pathology.Tenotomy and tenodesis have been shown to produce favourable and comparable results in treating LHB lesions, but a controversy still exists regarding the treatment of choice. Some suggest that tenotomy should be reserved for older, low-demand patients, while tenodesis should be performed in younger patients and those who engage in heavy labor. Proponents of tenotomy suggest that this is a technically easy procedure that leads to easy rehabilitation and fast return to activity with a low complication and reoperation rate. However, those who support LHB tenodesis list good preservation of elbow flexion and supination strength, improvement of functional scores, elimination of pain, and avoidance of cosmetic deformity as benefits of the procedure. Alternatively, the LHB can be maintained in the joint without tenodesis or tenotomy. In fact, it has not been clearly shown that LHB tenodesis or tenotomy leads to improved outcomes compared to leaving the biceps tendon intact. The primary goal of this prospective multicenter randomized study is to evaluate whether LHB tenodesis grants superior post-operative functional outcomes compared to LHB tenotomy or leaving the LHB intact in patients undergoing rotator cuff repair (RCR) for an isolated full-thickness lesion of the supraspinatus. The primary goal of this prospective multicenter randomized study is to evaluate whether LHB tenodesis grants superior post-operative functional outcomes compared to LHB tenotomy or leaving the LHB intact in patients undergoing rotator cuff repair (RCR) for an isolated full-thickness lesion of the supraspinatus. The secondary goals are to determine whether there is a difference in post-operative functional outcomes between the LHB tenotomy group and the Intact LHB group, and if there is a difference in complication rates or patient satisfaction between the three groups.

02

Conditions studied

  • Supraspinatus Tear

Keywords

  • Long head of the biceps
  • Supraspinatus tear
  • tenotomy
  • tenodesis
  • rotator cuff repair
03

In context

Lead sponsor

La Tour Hospital is the lead sponsor of 14 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient voluntarily consents to participate in the study and has the mental and physical ability to participate in the study, fill out subjective questionnaires, return for follow-up visits, and comply with prescribed post-operative physical therapy.
  • Full thickness tear of the supraspinatus tendon
  • Intact subscapularis tendon
  • Primary rotator cuff repair
  • Age 50-80

Exclusion criteria

Exclusion Criteria:

  • Previous full thickness biceps tear
  • Infection and neuropathic joints
  • Known or suspected non-compliance, drug or alcohol abuse
  • Patients incapable of judgement or under tutelage
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, contraindication for MRI scan etc.
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
  • Patient declines to participate in study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • No intervention
    Leaving LHB Intact

    The long head of the biceps (LHB) will be left intact.

  • Experimental
    LHB tenotomy

    The long head of the biceps (LHB) will be cut at its origin.

    Procedure: LHB Tenotomy

  • Experimental
    LHB Tenodesis

    The long head of the biceps (LHB) will be cut at its origin and reattached.

    Procedure: LHB Tenodesis

Interventions

  • ProcedureLHB Tenotomy

    Will be performed arthroscopically by cutting the LHB at its origin with arthroscopic scissors

  • ProcedureLHB Tenodesis

    "ill be performed arthroscopically with a tenodesis at the top of the articular margin using an onlay technique.

06

What researchers measure

Primary outcomes

  1. ASES score

    American Shoulder and Elbow Surgeon (ASES) score. From 0 (worst) to 100 (best).

    Time frame: At 24 post-operative months

Secondary outcomes

  1. VAS pain

    Visual analog scale (VAS) pain. From 0 (best) to 10 (worst)

    Time frame: At 24 post-operative months

  2. SSV

    Subjective Shoulder Value (SSV). From 0 (worst) to 100 (best).

    Time frame: At 24 post-operative months

  3. LHB score

    Long head of the biceps (LHB) score. From 0 (worst) to 100 (best).

    Time frame: At 24 post-operative months

  4. AFF

    Anterior Forward Flexion. In degrees. Will be performed with a goniometer by an independent investigator

    Time frame: At 24 post-operative months

  5. ER at side

    External Rotation at the side. In degrees. Will be performed with a goniometer by an independent investigator

    Time frame: At 24 post-operative months

  6. IR

    Internal Rotation to nearest spinal level. Will be performed with a goniometer by an independent investigator

    Time frame: At 24 post-operative months

  7. Complications

    Any type of post-operative complication

    Time frame: Within 2 postoperative years

  8. Patient satisfaction

    Yes or no

    Time frame: At 24 post-operative months

  9. Location of the defect (at the foot print | medial cuff failure)

    Radiographic outcome evaluated using an ultrasound examination.

    Time frame: At 6 post-operative month

  10. Status of the biceps tendon (intact | in continuity | defect)

    Radiographic outcome evaluated using an ultrasound examination.

    Time frame: At 6 post-operative month

  11. Signs of anchor displacement and location (lateral | medial row).

    Radiographic outcome evaluated using an ultrasound examination.

    Time frame: At 6 post-operative month

  12. Tendon thickness

    Radiographic outcome evaluated using an ultrasound examination.

    Time frame: At 6 post-operative month

  13. Number of patients with bursitis

    Radiographic outcome evaluated using an ultrasound examination.

    Time frame: At 6 post-operative month

  14. Number of patients with healing of the Supraspinatus tear according to Sugaya classification

    Radiographic outcome evaluated using an ultrasound examination.

    Time frame: At 6 post-operative month

  15. Number of patients with liquid in the bicipital sheath

    Radiographic outcome evaluated using an ultrasound examination.

    Time frame: At 6 post-operative month

  16. Number of patients with hypervascularization of the sheath

    Radiographic outcome evaluated using an ultrasound examination.

    Time frame: At 6 post-operative month

07

Study locations

4 of 4 sites recruiting
  • Sports Medicine and Shoulder Surgery, University of Michigan
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
    Recruiting
  • Group 23 Sports Medicine
    Calgary, Alberta T3B 6B7, Canada
    Recruiting
  • la Tour hospital
    Meyrin, Geneva 1217, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05660031
Lead sponsor
La Tour Hospital
Responsible party
Dr. Alexandre Lädermann (Orthopaedic Surgeon FMH, Shoulder and Elbow Surgery Traumatology, La Tour Hospital) — Principal investigator
First posted
Dec 21, 2022
Start date
Jun 1, 2021
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Apr 25, 2025

Study contacts

Alexandre Lädermann, MD
Contact
alexandre.laedermann@gmail.com
+41 22 71 975 55
Alexandre Lädermann, MD
principal investigator · La Tour Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion